ArticleGastro hep advances2026
Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: A subset of patients with autoimmune hepatitis (AIH) fail to achieve or sustain a complete biochemical response (CBR) to standard immunosuppression, resulting in a significant unmet clinical need. Rituximab, an anti-CD20 monoclonal antibody, has been investigated in refractory AIH, but prospective data remain limited. We sought to characterize the biochemical response and corticosteroid-sparing effects of rituximab in patients with difficult-to-manage AIH. Methods: We report a prospective case series of adults with difficult-to-manage AIH enrolled in the Genetic Repository of Autoimmune Liver Disease and Contributing Exposures cohort at Indiana University and treated with rituximab (1000 mg intravenously on days 1 and 15). Eligible patients had refractory disease, corticosteroid dependence, or inadequate biochemical control. Response was assessed at 12, 24, and 48 weeks. CBR was defined as normalization of alanine aminotransferase, aspartate aminotransferase, and immunoglobulin G. Analyses of biochemical outcomes were restricted to patients with active baseline disease. Results: Seven patients were enrolled; 6 had abnormal baseline biochemical indices. Biochemical improvement at 24 weeks was observed in all 6 patients with active baseline disease (100%), with 1 patient (16.7%) achieving CBR. However, response durability was limited, and biochemical worsening between 24 and 48 weeks occurred in 4 of 6 patients (66.7%). Response patterns included insufficient response with subsequent attenuation (n = 4), sustained CBR (n = 1), and early response followed by relapse (n = 1). Median prednisone-equivalent dose decreased from 30 mg/day at baseline to 12.5 mg/day at 48 weeks (-58.3%). No serious adverse events, infections, or hepatic decompensation occurred. Conclusion: In this prospective cohort of difficult-to-manage AIH, rituximab produced early biochemical improvement and a sustained corticosteroid-sparing effect, but a durable biochemical remission was uncommon. These data support further prospective evaluation of rituximab and next-generation B-cell-directed therapies in refractory AIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.